Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was upgraded by equities researchers at Canaccord Genuity from a “hold” rating to a “buy” rating in a report issued on Friday. The brokerage currently has a $484.00 price target on the …
BNS14d
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported earnings on May 4, 2017, and although it missed on the bottom line, REGN stock is still surging higher by 5.51% on the back of a positive reinforcement of forward guidance. I …
Stock
if REGN Stock Does THIS The $440.00 price has caused trouble for REGN stock, as it has turned away prices on more than one occasion. This level must be broken to the upside for REGN stock to resume its trend toward higher prices. …
Regeneron Pharmaceuticals is having a relatively strong start to the day today, and for good reason. The company received Fast Track Designation with regard to one of its lead candidates. As a result, investors got exciting, pushing …
Gain
As it reflects the theoretical cost of buying the company’s shares, the market cap of Regeneron Pharmaceuticals, Inc. …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Teva Pharmaceutical (NYSE:TEVA) provided an update on …
The quarter had decent Eylea numbers and an early encouraging Dupixent signal. Add to that Regeneron is unloved - bottom decile crowding score - and the stock moved well. Looking forward, the next set of data points is around …
Regeneron
Now Let me show you how we posted a buy call on Regeneron Pharmaceuticals Inc(NASDAQ:REGN) when the …
NASDAQ
Teva shares were not active in premarket trade. Regeneron shares declined 0.6% over the last three months, compared with a 1.3% decline in the S&P 500 SPX, -0.15% Teva stock declined 20.8% over the last three months.
Regeneron Pharmaceuticals (NASDAQ:REGN) has enjoyed a large, five-year 2,000 percent return, and while much is tied to its current growth, the vast majority of Regeneron’s $30 billion market cap is more-so tied to its pipeline. With that …